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Breast cancer has been the most frequently diagnosed malignancy and it is the leading cause of cancer death in women.[1](#cas13180-bib-0001){ref-type="ref"} Being a heterogeneous disease, breast cancer has at least five major tumor subtypes. Different subtypes carry different risks and prognoses.[2](#cas13180-bib-0002){ref-type="ref"} Although we have different treatment methods for different genetic types of breast cancer, these analyses have yet to alleviate metastatic and recurrence risk.[3](#cas13180-bib-0003){ref-type="ref"} Up to 30% of breast cancer patients diagnosed with early stage disease suffer metastatic and recurrent process, which greatly contributes to the aggressiveness and malignant degree of the tumor.[4](#cas13180-bib-0004){ref-type="ref"} Thus, the molecular mechanisms of breast cancer are poorly understood and will not be discussed further here.

Epithelial--mesenchymal transition (EMT) is a complex process that leads to mammary epithelial cells (MECs) to acquire highly migratory fibroblastic‐like features.[5](#cas13180-bib-0005){ref-type="ref"}, [6](#cas13180-bib-0006){ref-type="ref"} The malleability of MECs makes them dedifferentiate during EMT. In this way, transitioning MECs acquire a spindle‐shaped appearance characteristic of mesenchymal cells.[7](#cas13180-bib-0007){ref-type="ref"} Inappropriate reactivation of EMT is associated with cell invasion and metastasis in breast cancer.[8](#cas13180-bib-0008){ref-type="ref"} Transforming growth factor‐β (TGF‐β) is a multifunctional cytokine that regulates numerous physiological processes, such as cellular differentiation, homeostasis, and EMT.[9](#cas13180-bib-0009){ref-type="ref"} It is a tumor suppressor that can suppress mammary tumorigenesis by preventing MEC proliferation, or by inducing MEC apoptosis.[10](#cas13180-bib-0010){ref-type="ref"} During mammary tumorigenesis, genetic and epigenetic events undermine the tumor suppressive functions of TGF‐β, so making the cells acquire invasive and metastatic phenotypes in response to TGF‐β. Recent findings have implicated TGF‐β is a master regulator of EMT in normal and malignant MECs,[11](#cas13180-bib-0011){ref-type="ref"} and stimulate EMT with the acquisition of "stemness" in transitioning MECs,[12](#cas13180-bib-0012){ref-type="ref"} and with the selection and expansion of breast cancer stem cells. In brief, TGF‐β has the power to induce EMT that stimulates metastatic progression in breast cancer.[13](#cas13180-bib-0013){ref-type="ref"}

Delta‐aminolevulinate dehydratase (ALAD) is encoded by the *ALAD* gene. It catalyzes the second step in the biosynthesis of heme and is also an endogenous inhibitor of the 26S proteasome. Recent research has suggested that ALAD and lead exposure related to cancer risk.[14](#cas13180-bib-0014){ref-type="ref"}, [15](#cas13180-bib-0015){ref-type="ref"} A number of studies indicate ALAD variants related to risk of the renal cell carcinoma,[16](#cas13180-bib-0016){ref-type="ref"} prostate cancer,[17](#cas13180-bib-0017){ref-type="ref"} and brain tumors.[18](#cas13180-bib-0018){ref-type="ref"} There have been no reports regarding the correlation between ALAD and breast cancer, until now. In our study, we found that downregulated ALAD is associated with a mesenchymal phenotype and poor prognosis in breast cancer that could regulate the TGF‐β‐mediated EMT in breast cancer cells. Although the research is not definitive about the molecular mechanisms on EMT mediating the initiation and resolution of breast cancer metastasis, our study suggested that ALAD could inhibit the mesenchymal phenotype and suppress breast cancer progression by its involvement in TGF‐β‐induced EMT.

Materials and Methods {#cas13180-sec-0002}
=====================

Cell culture and clinical samples {#cas13180-sec-0003}
---------------------------------

MCF10A, MCF7, T47D, BT474, MDA‐MB‐468, MDA‐MB‐231 and MDA‐MB‐435 cell lines were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured as previously described.[19](#cas13180-bib-0019){ref-type="ref"} Cells were used within 6 months of resuscitation.

A total of 188 primary breast cancer specimens and 30 cases of adjacent histological normal tissues were obtained from patients who underwent breast surgery in Tianjin Medical University Cancer Institute and Hospital (Tianjin, China). All tumors were from patients with newly diagnosed breast cancer who had received no therapy before sample collection. After radical mastectomy, the primary breast cancer tissue and adjacent normal tissues were flash‐frozen in liquid nitrogen and stored at −80°C. This study was approved by the Institutional Review Board of the Tianjin Medical University Cancer Institute and Hospital and written consent was obtained from all participants.

Antibodies, reagents, plasmids, and siRNAs {#cas13180-sec-0004}
------------------------------------------

Antibodies against N‐cadherin, E‐cadherin, vimentin, ZEB1, (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Snail (Abcam, Cambridge, MA, USA), and β‐actin (Cell Signaling Technology, Beverly, MA, USA) were used. Recombinant human TGF‐β1 was purchased from R&D Systems (Redmond, WA, USA). The ORF of the human *ALAD* gene was amplified by PCR in the MCF10A cell line, and the amplified fragments were subcloned into the pcDNA3.1‐HA vector. The *ALAD* gene‐specific siRNA and non‐specific control siRNA were purchased from RiboBio (Guangzhou, China).

RNA extraction and RT--quantitative PCR {#cas13180-sec-0005}
---------------------------------------

The total RNA of cultured cells and surgically resected fresh breast tissues were extracted using mirVana PARIS kit (Life Technologies, Gradn Island, NY, USA) according to the manufacturer\'s instruction. Reverse transcription was performed using a First Strand cDNA Synthesis kit (TaKaRa, Dalian, China), according to the manufacturer\'s instruction. The real‐time quantitative PCR (qPCR) was carried out using GoTaq qPCR Master Mix (Promega, Madison, WI, USA) on a Bio‐Rad iQ5 Optical System (Bio‐Rad, Richmond, CA, USA). β‐Actin was used as an internal control.

Western blot analysis, immunofluorescence, and immunohistochemistry {#cas13180-sec-0006}
-------------------------------------------------------------------

Total protein was extracted by lysing the cells with RIPA buffer and protease inhibitor. After denaturing, proteins were run in 10% SDS‐PAGE gel and transferred to PVDF membranes. Membranes were blocked in 5% skim milk for 1 h at room temperature. Primary antibody was incubated overnight at 4°C. After washing in TBST, membranes were incubated with secondary antibody at room temperature for 1 h. Protein bands were visualized by the ECL system (Millipore, Bedford, MA, USA).

For immunofluorescence assay, cells were seeded in a 24‐well plate. The attached cells were fixed by 4% paraformaldehyde for 30 min, and penetrated by 0.5% Triton X‐100 for 15 min, then blocked by 3% BSA for 1 h. The cells were then incubated with primary antibody in 1% BSA overnight at 4°C. After washed with PBS, the cells was incubated with fluorescein isothiocyanate or phycoerythrin‐conjugated secondary antibodies at room temperature for 1 h and then stained with DAPI. Finally, coverslips were observed under a fluorescence microscope.

Expression of ALAD, E‐cadherin, and vimentin in breast cancer tissues was detected by immunohistochemical staining as previously described[20](#cas13180-bib-0020){ref-type="ref"} and were scored as negative and positive using 20% positive staining cut‐off. The specimens were observed by two pathologists.

Transforming growth factor‐β signaling analysis {#cas13180-sec-0007}
-----------------------------------------------

The TGFβ signaling activity was determined by Cignal SMAD Reporter Assay Kits (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions. The SMAD reporter is a mixture of an inducible SMAD‐responsive luciferase construct and a constitutively expressing Renilla construct. TGFβ signaling activity was detected by using a dual luciferase assay kit (Promega) according to the manufacturer\'s recommendations. The results were normalized against Renilla luciferase activity. All transfections were performed in triplicate.

Apoptosis assay {#cas13180-sec-0008}
---------------

The cells were collected after 48 h of transfection. The cell apoptosis ratio was analyzed using an annexin V--FITC apoptosis detection kit (BD Biosciences, San Diego, CA, USA) according to the manufacturer\'s instructions. Apoptosis cells were analyzed by FACS.

Proliferation and invasion assays {#cas13180-sec-0009}
---------------------------------

Both MTT and plate colony formation assays were used to evaluate the ability of cell proliferation. For MTT assay, 24 h after transfection, 5 × 10^3 ^cells/well were seeded in 96‐well plates. After incubation for the indicated time, the cells were incubated with 10 μL MTT (0.5 mg/mL; Sigma‐Aldrich, St Louis, MO, USA) at 37°C for 4 h. Then, the medium was removed, and precipitated Formosan was dissolved in 150 μL DMSO. The absorbance at 570 nm was detected using a microplate autoreader (Bio‐Rad). For the plate colony formation assay, 24 h after transfection, 500 cells/well were seeded in 6‐well plates. After approximately 2 weeks, the colonies obtained were washed with PBS and fixed with 10% formalin for 15 min at room temperature, then washed with PBS and stained with hematoxylin. The colonies were counted and compared with control cells.

The invasive ability of breast cancer cells *in vitro* was evaluated by Matrigel‐coated Transwells. Briefly, 5 × 10^4^ cells in 500 μL serum‐free medium were added to the upper chamber, and medium containing 20% FBS was added into the lower chamber. Twenty‐four hours later, the migrant cells that had attached to the lower surface were fixed with 20% methanol and stained for 20 min with crystal violet. The membranes were then carved and embedded under coverslips with the cells on the top. The number of migrating cells was counted under a microscope in five predetermined fields.

Independent datasets for validation {#cas13180-sec-0010}
-----------------------------------

The validation study was carried out using Gene Expression‐based Outcome for Breast Cancer Online (GOBO; <http://co.bmc.lu.se/gobo>). This is an online tool for prognostic validation of single genes, sets of genes, or simple predictors in a pooled breast cancer dataset analyzed using Affymetrix U133A arrays (St Louis, MO, USA). Seven public datasets (accession nos. [GSE11121](GSE11121), [GSE12093](GSE12093), [GSE2034](GSE2034), [GSE2603](GSE2603), [GSE5327](GSE5327), [GSE6532](GSE6532), and [GSE7390](GSE7390)), which contain the DFS information, were included in the validation of prognostic value of ALAD mRNA levels.

Statistical analysis {#cas13180-sec-0011}
--------------------

All the experiments were carried out at least twice independently and data are presented as mean ± SEM. All statistical analyses were undertaken using [spss]{.smallcaps} 18.0 software for Windows (SPSS Inc., Chicago, IL, USA). For paired samples, the statistical significance of difference was calculated using Wilcoxon\'s signed rank with significant differences defined as at least a *P*‐value of \<0.05.

Results {#cas13180-sec-0012}
=======

*ALAD* is downregulated and associated with a mesenchymal phenotype in breast cancer {#cas13180-sec-0013}
------------------------------------------------------------------------------------

To explore the influence of ALAD on breast cancer development and progression, we first examined the expression of *ALAD* in 30 cases of breast cancer tissues and paired normal breast tissues by RT‐qPCR. As shown in Figure [1](#cas13180-fig-0001){ref-type="fig"}(a), *ALAD* mRNA expression was downregulated in breast cancer tissues compared with adjacent normal breast tissues. To further validate the expression of *ALAD* in breast cancer and normal tissues, we analyzed the *ALAD* mRNA expression profiling dataset from the starBase version 2.0 project including 998 cases of breast cancer tissues and 108 cases of normal breast tissues.[21](#cas13180-bib-0021){ref-type="ref"}, [22](#cas13180-bib-0022){ref-type="ref"} The validation data confirmed that *ALAD* mRNA expression was downregulated in breast cancer tissues (Fig. [1](#cas13180-fig-0001){ref-type="fig"}b). We next examined the expression of *ALAD* in six breast cancer cell lines (T47D, MCF7, BT474, MDA‐MB‐231, MDA‐MB‐468, and MDA‐MB‐435) and breast epithelial cell line MCF10A by RT‐qPCR and Western blot analysis. At the mRNA level, the breast epithelial cell line MCF10A showed high expression level of *ALAD*, whereas the basal‐like breast cancer cell lines MDA‐MB‐231, MDA‐MB‐468, and MDA‐MB‐435 showed low expression levels of *ALAD* (Fig. [1](#cas13180-fig-0001){ref-type="fig"}c). We confirmed the expression level of ALAD at the protein level (Fig. [1](#cas13180-fig-0001){ref-type="fig"}d). Furthermore, the high *ALAD*‐expressing cell lines showed high expression levels of E‐cadherin and low expression levels of vimentin (Fig. [1](#cas13180-fig-0001){ref-type="fig"}d). These results suggested that *ALAD* is downregulated in breast cancer cells and low levels of *ALAD* expression are related to a mesenchymal phenotype.

![Delta‐aminolevulinate dehydratase (ALAD) expression is downregulated and associated with a mesenchymal phenotype in human breast cancer. (a) Expression of *ALAD* mRNA was assessed in human breast cancer tissues and paired adjacent normal breast tissues by RT--quantitative PCR. (b) Analysis of *ALAD* mRNA expression based on gene expression profiling data from starBase version 2.0. (c) Expression of *ALAD* mRNA was detected in human breast cancer cell lines by RT--quantitative PCR. (d) Expression of ALAD, E‐cadherin, and vimentin protein in human breast epithelial cell line MCF10A and six breast cancer cell lines as determined by Western blot analysis.](CAS-108-604-g001){#cas13180-fig-0001}

*ALAD* suppresses breast cancer progression {#cas13180-sec-0014}
-------------------------------------------

To investigate whether *ALAD* regulates breast cancer progression, we transiently transfected MDA‐MB‐231 cells with a human ALAD expression vector (Fig. [2](#cas13180-fig-0002){ref-type="fig"}a). We observed that cell proliferation was significantly reduced in *ALAD*‐overexpressing MDA‐MB‐231 cells by MTT (Fig. [2](#cas13180-fig-0002){ref-type="fig"}b) and colony formation assays (Fig. [2](#cas13180-fig-0002){ref-type="fig"}c). Moreover, overexpression of *ALAD* decreased the *in vitro* invasion of the transfected cells (Fig. [2](#cas13180-fig-0002){ref-type="fig"}d). Furthermore, the number of apoptotic cells was significantly higher in *ALAD*‐overexpressing MDA‐MB‐231 cells (Fig. [2](#cas13180-fig-0002){ref-type="fig"}e). Next, we examined the effect of the siRNA knockdown of *ALAD* in MCF10A cells (Fig. [2](#cas13180-fig-0002){ref-type="fig"}f), which normally have high *ALAD* expression, to determine whether depletion of ALAD affects breast cancer progression. The results from MTT (Fig. [2](#cas13180-fig-0002){ref-type="fig"}g) and colony formation (Fig. [2](#cas13180-fig-0002){ref-type="fig"}h) assays revealed that MCF10A cells transfected with *ALAD* siRNA showed an increase in cell proliferation compared with cells transfected with control siRNA. Invasive ability was also elevated in ALAD‐depleted MCF10A cells (Fig. [2](#cas13180-fig-0002){ref-type="fig"}i). The same results were also observed in MDA‐MB‐468 and T47D cells (Fig. [S1](#cas13180-sup-0001){ref-type="supplementary-material"}). These results suggested that ALAD suppresses breast cancer progression.

![Delta‐aminolevulinate dehydratase (ALAD) inhibits breast cancer progression and promotes apoptosis. (a) Expression of ALAD protein in indicated MDA‐MB‐231 cells by Western blot analysis. (b,c) Proliferative ability of cells as in (a) determined by MTT (b) and colony formation (c) assays. (d) Invasive ability of cells as in (a) determined by Transwell assay. (e) Apoptotic cells as in (a) determined by FACS. (f) ALAD expression in indicated MCF10A cells by Western blot analysis. (G,H) Proliferative ability of cells as in (f) determined by MTT (g) and colony formation (h) assays. (i) Invasive ability of cells as in (f) determined by Transwell assay. \*\**P* \< 0.01; \*\*\**P* \< 0.001.](CAS-108-604-g002){#cas13180-fig-0002}

*ALAD* inhibits the mesenchymal phenotype in breast cancer cells {#cas13180-sec-0015}
----------------------------------------------------------------

Next, we observed that overexpression of *ALAD* inhibited the mesenchymal spindle‐like morphology in MDA‐MB‐231 cells (Fig. [3](#cas13180-fig-0003){ref-type="fig"}a). We then examined both epithelial and mesenchymal markers by RT‐qPCR (Fig. [3](#cas13180-fig-0003){ref-type="fig"}b), Western blot analysis (Fig. [3](#cas13180-fig-0003){ref-type="fig"}c), and immunofluorescence (Fig. [3](#cas13180-fig-0003){ref-type="fig"}d). As can be seen, the *ALAD*‐overexpressing MDA‐MB‐231 cells showed a significant downregulation of vimentin and N‐cadherin, whereas the epithelial marker E‐cadherin was dramatically upregulated. Reverse transcription--qPCR and Western blot analyses also revealed the inhibition of EMT‐related factors Snail and ZEB1 in ALAD‐expressing MDA‐MB‐231 cells (Fig. [3](#cas13180-fig-0003){ref-type="fig"}b,c). Thus, our study suggested that *ALAD* could inhibit the mesenchymal phenotype in breast cancer cells.

![Delta‐aminolevulinate dehydratase (ALAD) suppresses the epithelial--mesenchymal transition‐like phenotype in MDA‐MB‐231 cells. (a) Cellular morphology of *ALAD*‐overexpressing MDA‐MB‐231 and control cells. (b) Expression of vimentin, N‐cadherin, E‐cadherin, Snail, and ZEB1 mRNA was determined by RT--quantitative PCR in indicated cells. (c) Expression of vimentin, N‐cadherin, E‐cadherin, Snail, and ZEB1 protein was determined by Western blot analysis in indicated cells. (d) Immunofluorescence of vimentin and E‐cadherin in indicated cells. \*\*\**P* \< 0.001.](CAS-108-604-g003){#cas13180-fig-0003}

*ALAD* regulates the TGF‐β‐mediated EMT‐like phenotype in breast cancer cells {#cas13180-sec-0016}
-----------------------------------------------------------------------------

Transforming growth factor‐β signaling is central to carcinogenesis and cancer progression because it regulates a variety of critical cellular processes, including EMT. Thus, we investigated the role of *ALAD* in TGF‐β signaling. We observed that ALAD was suppressed in a dose‐ and time‐dependent manner following the addition of TGF‐β to the cell culture medium by RT‐qPCR (Fig. [4](#cas13180-fig-0004){ref-type="fig"}a,b). To investigate whether downregulation of *ALAD* is required for TGF‐β‐induced EMT‐like phenotype, we overexpressed *ALAD* in MCF10A cells and examined their responses to treatment with TGF‐β1. MCF10A cells transfected with vector control displayed an elongated fibroblast‐like morphology, whereas *ALAD*‐transfected cells retained their cobblestone‐like morphology after TGF‐β1 treatment (Fig. [4](#cas13180-fig-0004){ref-type="fig"}c). To confirm whether TGF‐β plays an important role in the oncogenic function of *ALAD*, we used the luciferase assay to determine the effect of *ALAD* on the TGF‐β signaling activity. As shown in Figure [4](#cas13180-fig-0004){ref-type="fig"}(d), the TGF‐β activity was significantly enhanced in MCF10A cells after TGF‐β1 treatment. Furthermore, in MCF10A cells transfected with ALAD, the addition of TGF‐β1 did not affect the TGF‐β signaling (Fig. [4](#cas13180-fig-0004){ref-type="fig"}d). We than examined both epithelial and mesenchymal markers by Western blot analysis. Consistent with morphologic changes, E‐cadherin expression was decreased, while vimentin expression was increased in MCF10A cells after TGF‐β1 treatments, but neither changed expression in *ALAD*‐expressing MCF10A cells (Fig. [4](#cas13180-fig-0004){ref-type="fig"}e). Our previous study indicated that TGF‐β inhibitor SB431542 suppresses cancer progression in MDA‐MB‐231 cells.[23](#cas13180-bib-0023){ref-type="ref"} To further confirm the role of *ALAD* in TGF‐β signaling, we added the TGF‐β inhibitor SB431542 in ALAD‐depleted MCF10A cells. We observed that the expression of E‐cadherin was downregulated, whereas the expression of vimentin was upregulated, in ALAD‐depleted MCF10A cells compared with that of control cells (Fig. [4](#cas13180-fig-0004){ref-type="fig"}f). Moreover, depletion of ALAD could partly reduce the SB431542‐induced changes in MCF10A cells (Fig. [4](#cas13180-fig-0004){ref-type="fig"}f,g). These results suggest that ALAD is involved in TGF‐β‐induced EMT.

![Delta‐aminolevulinate dehydratase (ALAD) regulates transforming growth factor‐β (TGF‐β)‐mediated epithelial--mesenchymal transition in MCF10A cells. (a,b) RT--quantitative PCR analysis of *ALAD* expression levels in MCF10A cells treated with TGF‐β1 at indicated concentrations (a) and time (b) compared to the control. (c) Morphology of MCF10A cells with Control and ALAD after 7 days of treatment with TGF‐β1 (10 ng/mL) in MCF10A cells. (d) TGF‐β signaling activity determined by luciferase report assay. (e,f) Western blot of E‐cadherin, vimentin, and ALAD expression in indicated MCF10A cells. (g) Invasive ability of indicated MCF10A cells. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.](CAS-108-604-g004){#cas13180-fig-0004}

*ALAD* downregulation is associated with poor prognosis in patients with breast cancer {#cas13180-sec-0017}
--------------------------------------------------------------------------------------

To examine whether the biological effects of *ALAD* on breast cancer progression were clinically relevant, we assessed its expression in 188 cases of breast cancer tissues. We then subdivided the tumors into two groups according to receiver operating characteristic curve and the optimal cut‐off value was defined to classify all patients into distinguished prognosis groups (Fig. [S2](#cas13180-sup-0002){ref-type="supplementary-material"}). The sensitivity and specificity were 0.500 and 0.707, respectively. The cut‐off value 2 × 10^−3^ was used to group patients into low *ALAD* expression (ALAD~low~, *n* = 55) and high *ALAD* expression groups (ALAD~high~, *n* = 133). The association between *ALAD* expression and clinicopathological factors are shown in Table [1](#cas13180-tbl-0001){ref-type="table-wrap"}. A Kaplan--Meier survival analysis revealed that patients in the ALAD~high~ group had a more favorable outcome than those in the ALAD~low~ group (Fig. [5](#cas13180-fig-0005){ref-type="fig"}a). The result was confirmed by GOBO that patients with high *ALAD* expression had a favorable outcome (Fig. [5](#cas13180-fig-0005){ref-type="fig"}b). To confirm the *in vitro* finding that TGF‐β‐mediated mesenchymal phenotype and inhibition of ALAD are correlated in breast cancer cells, we evaluated the expression levels of *ALAD*, E‐cadherin, and vimentin by immunochemistry in 150 breast cancer patient samples. We found that the percentage of samples with ALAD^neg.^/E‐cadherin^neg.^/vimentin^pos.^ or ALAD^pos.^/E‐cadherin^pos.^/vimentin^neg.^ was 50.7% (Table [2](#cas13180-tbl-0002){ref-type="table-wrap"}; *P* \< 0.001).

###### 

Association between delta‐aminolevulinate dehydratase (ALAD) expression levels and clinicopathological factors in 188 breast cancer patients

  Clinicopathological factors   ALAD~high~ (*n* = 133)   ALAD~low~ (*n* = 55)   *P*‐value
  ----------------------------- ------------------------ ---------------------- -----------
  Age, years                                                                    
  \<55                          84                       40                     0.239
  ≥55                           49                       15                     
  Menopausal status                                                             
  Pre                           61                       33                     0.055
  Post                          72                       22                     
  Tumor size, cm                                                                
  ≤2                            31                       7                      0.114
  \>2                           102                      48                     
  Clinical stage                                                                
  I+II                          115                      42                     0.129
  III                           18                       13                     
  Histological grade                                                            
  I+II                          121                      38                     0.001
  III                           12                       17                     
  Lymph node status                                                             
  Negative                      54                       17                     0.249
  Positive                      79                       38                     
  ER status                                                                     
  Positive                      84                       25                     0.034
  Negative                      49                       30                     
  PR status                                                                     
  Positive                      68                       25                     0.523
  Negative                      65                       30                     
  HER‐2 status                                                                  
  Negative                      90                       38                     1.000
  Positive                      43                       17                     

ER, estrogen receptor; HER‐2, human epidermal growth factor receptor‐2; PR, progesterone receptor.
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![Delta‐aminolevulinate dehydratase (*ALAD*) downregulation is associated with poor prognosis in patients with breast cancer. (a) Kaplan--Meier analysis of *ALAD* expression in 188 cases of breast cancer. (b) Kaplan--Meier analysis of breast cancer patients with different *ALAD* expression by Gene Expression‐based Outcome for Breast Cancer Online.](CAS-108-604-g005){#cas13180-fig-0005}

###### 

Relationship between delta‐aminolevulinate dehydratase (ALAD) and E‐cadherin/vimentin expression in 150 breast cancer patient samples

  Expression                          ALAD^pos.^   ALAD^neg.^
  ----------------------------------- ------------ ------------
  E‐cadherin^pos.^ + vimentin^pos.^   11 (7.3)     15 (10.0)
  E‐cadherin^neg.^ + vimentin^neg.^   9 (6.0)      18 (12.0)
  E‐cadherin^neg. ^+ vimentin^pos.^   8 (5.3)      55 (36.7)
  E‐cadherin^pos.^ + vimentin^neg.^   21 (14.0)    13 (8.7)

Data are shown as *n* (%).

John Wiley & Sons, Ltd

Discussion {#cas13180-sec-0018}
==========

Delta‐aminolevulinate dehydratase is known as an important rate‐limiting enzyme in the porphyrin and heme biosynthetic pathway. It has been found to play a critical role in lead metabolism and susceptibility to lead toxicity. Report of the relation between ALAD and carcinogenesis is limited. We observed the low expression of ALAD in breast cancer tissues and cell lines, both at gene level and protein level, which suggested a tumor suppressor role in breast cancer progression. To confirm that effect, human ALAD expression vectors were transfected into breast cancer cell lines, leading to the reduction of proliferation and invasion capability. In addition, the ability of proliferation and invasion was elevated in breast epithelial cell line MCF10A as a result of the depletion of ALAD.

It was noted that the expression level of *ALAD* in basal‐like breast cancer cell lines MDA‐MB‐231, MDA‐MB‐468, and MDA‐MB‐435, which ordinarily show a mesenchymal spindle‐like morphology, was much lower than in the other cell lines. In addition, the mesenchymal morphology of MDA‐MB‐231 cells was transformed to epithelial‐like by *ALAD* overexpression. It was supposed that ALAD would be involved in the EMT process. Cells that undergo EMT often lose the epithelial phenotype with specific markers (e.g. E‐cadherin) and achieve the mesenchymal phenotype with other markers (e.g. N‐cadherin, vimentin). Transforming growth factor‐β signaling is thought to be the chief inducer of EMT as it plays dual roles in tumorigenesis.[24](#cas13180-bib-0024){ref-type="ref"}, [25](#cas13180-bib-0025){ref-type="ref"} Indeed, TGF‐β acts as tumor suppressor during the early stage of tumorigenesis, but ultimately promotes cancer progression.[26](#cas13180-bib-0026){ref-type="ref"}, [27](#cas13180-bib-0027){ref-type="ref"} The TGF‐β signaling pathway and various transcription factors, such as the Snail family, Twist, and ZEB respond to this signal and function as master controllers of the EMT program.[28](#cas13180-bib-0028){ref-type="ref"} It was shown in our study that ALAD was capable of inhibiting the TGF‐β‐induced EMT process. Cells were observed to become resistant against TGF‐β stimulation as a result of *ALAD* overexpression.

It is understood that EMT progress is essentially acquired for most cancer cells to obtain the ability of migration and invasion, which ultimately leads to metastasis. Inhibition of TGF‐β‐induced EMT by ALAD could reduce the cells' invasive capacity, which is consistent with our previous observations. It was also proved by clinical cases and the GOBO database that disease‐free survival of patients with high *ALAD* expression is significantly longer than in other groups.

In conclusion, our work revealed the relation between ALAD and breast cancer progress. We showed that ALAD could inhibit the TGF‐β‐induced EMT process and reduce the invasive capacity of cancer cells. These findings suggested that ALAD might be a potential suppressor of carcinogenesis. The molecular mechanism of its detailed role in cancer progress is still unclear, and its significance in the clinic should be established by further research.
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**Fig. S1.** Delta‐aminolevulinate dehydratase (ALAD) inhibits breast cancer progression and promotes apoptosis.

###### 

Click here for additional data file.
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**Fig. S2.** Receiver operating characteristic curve of the optimum cut‐off point for delta‐aminolevulinate dehydratase (ALAD) expression.

###### 

Click here for additional data file.
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